Early effectiveness and safety of a modified shorter all-oral regimen for MDR/RR-TB in China
W. Nie (Beijing, China), J. Du (Wuhan, China), Y. Liu (Qingdao, China), Q. Wu (Xi'an, China), F. Ren (Xi'an, China), Q. Cai (Hangzhou, China), Y. Zhang (Nanjing, China), N. Chu (Beijing, China)
Source: International Congress 2022 – Advances in the treatment and clinical/surgical management of tuberculosis and NTM
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. Nie (Beijing, China), J. Du (Wuhan, China), Y. Liu (Qingdao, China), Q. Wu (Xi'an, China), F. Ren (Xi'an, China), Q. Cai (Hangzhou, China), Y. Zhang (Nanjing, China), N. Chu (Beijing, China). Early effectiveness and safety of a modified shorter all-oral regimen for MDR/RR-TB in China. 2615
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|